Coagulation Factor Concentrates Market

Coagulation Factor Concentrates Market Outlook (2025 to 2035)

The global coagulation factor concentrates market is expected to grow at a constant rate, with a projected value of USD 9.77 billion in the year 2025. It is likely to be around USD 21.09 billion by the year 2035 at a CAGR of about 8.01%. This is driven by factors such as the growing cases of bleeding disorders and the expansion of therapeutic applications.

One of the major forces behind coagulation factor concentrates market is the increase in the diagnosis of hemophilia and other orphan bleeding disorders. Advances in diagnostic techniques and increased awareness have resulted in these diseases being diagnosed earlier and treated more intensively. Thus, there is demand for factor VIII, factor IX, and other coagulation factors concentrated in different healthcare systems.

The transition in treatment regimens from on-demand to prophylactic coagulation factor products has enormously increased consumption. Prophylactic dosing of coagulation factors decreases bleeding events and joint damage in the long term, especially in children and adolescents, and thus enhances quality of life and clinical benefits for patients with chronic bleeding disorders.

Furthermore, such complications as the formation of inhibitors-neutralizing antibodies against infused clotting factors-are formidable clinical challenges. Treating such complications may involve alternative treatments or immune tolerance induction, adding to both the complexity and expense of care for patients affected by them.

Trends like gene therapy and personalized medicine are also defining the future of the coagulation factor concentrates market. Gene therapy, while potentially a long-term competitor in the short to mid-term, is seeing continued demand for coagulation factor concentrates, especially as combination therapies and customized dosing approaches continue to evolve.

Also, the increasing population of geriatric patients undergoing surgery and invasive procedures drives demand. Geriatric patients with acquired bleeding disorders or anticoagulant-associated complications often require short-term factor supplementation, widening the therapeutic use beyond inherited disease.

The coagulation factor concentrates market is set for long-term and stable development over the coming decade. Through innovation, expanding access, and growth in the importance assigned to early and extended treatment, these life-saving medicines will continue squarely at the forefront of the management of bleeding disorders around the world.

Report Attributes	Details
Coagulation Factor Concentrates Market Size (2025E)	USD 9.8 billion
Coagulation Factor Concentrates Market Size (2035F)	USD 21.09 billion
Global Market Growth Rate (2025 to 2035)	8.01%
China Market Share (2025)	USD 0.75 billion
U.S. Market Share (2035)	USD 15 billion
Key Companies Profiled	CSL Behring; Grifols; Baxter International Inc.; Novo Nordisk A/S; Octapharma; Shire; Kedrion S.P.A.; LFB; Biotest; Green Cross Corporation; Shanghai RAAS Blood Products; Sanquin; Bio Product Laboratory; Medscape

Shifts in the Market from 2020 to 2024 and Future Trends 2025 to 2035

Between 2020 and 2024, the coagulation factor concentrates market was mainly driven by increasing awareness of bleeding disorders such as hemophilia A and B, followed by rising diagnostic rates and therapy accessibility in developed countries. Both public and private healthcare systems spent more on the availability of recombinant and plasma-derived factor concentrates to manage the disease more efficiently.

Pharmaceuticals like Takeda and CSL Behring consolidated their supply chains and expanded access to high-purity Factor VIII and IX products. Patient support programs and government reimbursement systems also enhanced long-term therapy adherence.

From 2025 to 2035, there will be a transition toward gene therapy and personalized solutions. Extended half-life recombinant concentrates with less frequent dosing will become more prevalent. Biotech firms also invest in gene editing platforms to possibly cure hemophilia.

Emerging industries in Latin America and Asia will experience growth through enhanced diagnostic infrastructure and local manufacturing initiatives. The manufacturers will also improve cold chain logistics and evaluate subcutaneous delivery forms for increased patient comfort and adherence.

A Comparative Market Shift Analysis (2020 to 2024 vs. 2025 to 2035)

2020 to 2024	2025 to 2035
More diagnosis of bleeding disorders, better access to therapy	Movement to gene therapy, individualized treatment, growth in emerging industries
Recombinant and plasma-derived Factor VIII and IX	Half-life extended products, gene-edited products
Increased plasma facilities, enhanced global supply chains	In investing in gene therapy, formulation of subcutaneous and long-acting versions
Sustained demand in North America and Europe	Accelerating adoption in Asia-Pacific, Middle East, and Latin America
Increased purity, improved safety profiles	Threading the needle, one-time regimens and cut infusion frequency
Product safety focus and plasma screening	Streamlined approval for gene editing tools and biotech-based therapies
Recurrent prophylactic infusions	Low-frequency, long-term, or maybe curative approaches

CAGR Comparison Table (2025 to 2035)

Country	CAGR (2025 to 2035)
The U.S.	6.3%
UK	5.7%
France	5.4%
Germany	5.8%
Italy	5.2%
South Korea	6.0%
Japan	5.5%
China	7.2%
Australia	5.6%
New Zealand	5.1%

The U.S.

The U.S. coagulation factor concentrates market is likely to witness a healthy CAGR of 6.3% between 2025 and 2035 on account of the high levels of awareness, strong healthcare infrastructure, and rising uptake of prophylactic treatment of hemophilia. High access to specialized hematology clinics, as well as robust diagnostics, are leading to early diagnosis and early treatment, respectively, and boosting market penetration. Apart from this, rising government support for the treatment of orphan diseases also continues to drive demand for recombinant factor concentrates.

Key leaders Pfizer Inc., CSL Behring, and Baxter International are spearheading the growth by developing new-generation products and forging strategic partnerships. Technologically advanced access to recombinant products and changing demand from plasma-based treatments towards new-generation concentrates are also positively driving trends. Sustained investments in R&D and the application of digital health technologies in hematology treatment are set to continue leading the U.S. worldwide.

UK

The UK coagulation factor concentrates market is anticipated to record a CAGR of 5.7% during the forecast period, owing to a well-structured National Health Service (NHS) and a strong emphasis on equal access to hemophilia care. Enhanced surveillance systems and participation in global treatment networks are facilitating early diagnosis and treatment optimization, thus driving the adoption of factor concentrates.

Sales expansion is assisted by the presence of top-of-the-line drug production firms like Bio Products Laboratory Ltd. and Grifols UK Ltd. Prophylactic treatment regimens increasing, especially in children and older adults living with hemophilia, impact both the recombinant and half-life extended coagulation factor pharmaceutical demand. In addition, technology convergence and public purchasing mechanisms assist with stable product availability and price.

France

The French coagulation factor concentrates market will grow at a CAGR of 5.4% in 2025-2035. Government health programs and robust reimbursement are major drivers of the widespread use of coagulation factor therapy across key population segments. Specialized hemophilia centers are helping patient compliance and enhancing clinical outcomes.

Some of the major players in France are Sanofi, LFB Group, and Octapharma. Growth driven by innovation, mainly through gene therapy and recombinant factor VIII and IX concentrations, is driving the future of treatment paradigms. Growth opportunities based on the growing demand for minimally invasive treatment modalities and the launch of long-acting therapeutic products are likely to generate long-term growth opportunities over the forecast period.

Germany

The coagulation factor concentrates market in Germany is also expected to advance at a CAGR of 5.8% from 2025 to 2035. An extremely advanced healthcare infrastructure, complemented by research centers and a focus on precision medicine, is also driving the penetration of precision hemophilia therapies. The extensive application of pharmacovigilance programs is also driving patient safety.

Key leaders are Bayer AG, Biotest AG, and CSL Behring. Higher investments in biopharmaceutical manufacturing capacity and robust regulatory framework are supporting the development and swift commercialization of new recombinant factor products. Rising demand for home-based infusion therapy is also fuelling patient access and treatment adherence in urban and rural areas.

Italy

The Italian coagulation factor concentrates market will experience a CAGR of 5.2% between the years 2025 and 2035. Improving treatment protocols and creating hemophilia registries are raising awareness and access to care. Successful support by national health authorities and the adoption of new therapies within hospital formularies are key drivers for growth.

Firms like Takeda and Kedrion Biopharma are leading the treatment industry in Italy. The coagulation factor concentrates market is also being supported by collaborative research among clinical centers and academic institutions with the aim of enhancing the long-term efficacy of treatments. Long half-life concentrations are also picking up pace, being more convenient to patients and providing more clinical advantages.

South Korea

South Korea's coagulation factor concentrates market will increase at 6.0% CAGR during the forecast period. Increased healthcare modernization and rising incidence of congenital bleeding disorders are fueling growth. Government assistance towards rare disease management and the addition of factors concentrated in national insurance schemes are increasing treatment access.

Coagulation factor concentrates market leaders like GC Biopharma and SK Plasma are establishing domestic manufacturing capabilities and launching innovative plasma-derived and recombinant factor therapies. Digital monitoring system integration and patient-centric treatment protocols are establishing new standards of disease management. Greater involvement in foreign clinical trials is most likely to continue to enhance product pipeline variety and clinical acumen.

Japan

Japan will experience a CAGR of 5.5% during the period 2025-2035 in the coagulation factor concentrates market. An established healthcare system and stringent regulations are facilitating uniform availability and acceptance of novel hemophilia treatments. Homogeneous industry growth is being driven by early diagnosis and personalized treatment strategies favored by national protocols.

Major players like Takeda Pharmaceutical Company and KM Biologics are investing in product development and building manufacturing capacity. Shift to extended half-life and subcutaneous products is enhancing patient compliance and treatment efficacy. Strategic collaborations between pharma firms and public health organizations will make Japan a regional coagulation factor research and treatment hub.

China

China's concentrates market for coagulation factors will experience the highest CAGR of 7.2% between 2025 and 2035. The main drivers of this high growth are higher healthcare penetration, rising hemophilia diagnosis rates, and greater government emphasis on orphan diseases. Reimbursement policies from the provinces and public-private collaborations are driving greater access to coagulation treatments in different provinces.

Key coagulation factor concentrates market players are China National Biotec Group and Sinopharm. Robust investment in the development of domestic biologics production facilities and forceful product development initiatives are stimulating growth. Government-sanctioned early disease screening programs and national registers are driving treatment coverage, while collaboration with international companies is boosting the development of new recombinant products.

Australia

Australia is expected to achieve a growth of 5.6% CAGR during the forecast period in the coagulation factor concentrates market. Strong national blood management systems and central supply systems are ensuring a level playing field for access to treatment between states. The ongoing updating of clinical practice guidelines is enabling the evidence-based use of recombinant and plasma-derived products.

Key players like CSL Behring and Novo Nordisk are pushing sales aggressively with more clinical support and training initiatives. The convergence of mobile health technology and home infusion therapy is increasing treatment flexibility and adherence. Growing recognition of hemophilia and related disorders will continue to stimulate demand for coagulation factor concentrates in the nation.

New Zealand

New Zealand's coagulation factor concentrates market is expected to experience a CAGR of 5.1% during 2025-2035. The coagulation factor concentrates market is dominated by an integrated health system and strong support for the management of rare diseases, with timely treatment and universal access to therapy. National procurement strategies and close interaction with specialist clinicians are stimulating growth.

Key players are Baxter Healthcare and Bioverativ. Prophylactic treatment regimens and long-acting coagulation factor product demand are driving future trends. Further extension of education programs and community-based care systems will be expected to enhance bleeding disorder patients' compliance with treatment and quality of life.

Segment-wise Analysis

By Type

The Coagulation Factor Concentrates Market in 2025 is expected to be led by Coagulation Factor IX, which will hold 50% of the coagulation factor concentrates market share, followed by Coagulation Factor XIII at 30%. The increasing prevalence of hemophilia, bleeding disorders, and advancements in recombinant coagulation factors are the primary drivers of growth.

The coagulation factor IX segment at 50% is primarily driven by its importance in treating hemophilia B, a rare genetic bleeding disorder. The growing adoption of recombinant Factor IX products, which provide enhanced safety and efficacy with longer half-lives and less infusion frequency, brings momentum to the overall coagulation factor concentrates market.

Major pharmaceutical companies such as CSL Behring, Pfizer (BeneFIX), and Novo Nordisk (Rebinyn) continue to innovate Factor IX therapies to improve patient outcomes and reduce treatment burdens. The North American and European regions continue to dominate this segment, attributed to advanced healthcare infrastructure, favorable reimbursement policies, and high awareness of hemophilia treatments.

The coagulation factor XIII segment at 30% is steadily growing, associated with its role in blood clot stabilization and wound healing. Individuals diagnosed with Factor XIII deficiency, although rarer than hemophilia B, are subjected to lifelong replacement therapy. Demand for specialized coagulation therapies in surgical and trauma care acts as a propellant for this segment.

The pharmaceutical companies are taking the lead in Factor XIII product development, including Takeda Pharmaceuticals (Tretten), CSL Behring (Corifact), and Grifols while aiming to improve efficacy, safety, and patient compliance. Asia-Pacific is a promising region because of improved healthcare access and the increased rates of diagnosis of coagulation disorders.

By End User

Drug therapy usually involves taking medicines or therapeutics by patients at hospitals or clinics. The coagulation factor concentrates market by Hospitals and Clinics is expected to grow with a 70% share of end users for the forecast of 2025 due to rising hemophilia, von Willebrand disease, bleeding disorders, and advancements in recombinant coagulation factors. 20% of research laboratories follow this.

The segment has been huge, with a share of 70% of patients availing these end-user facilities since the coagulation factor concentrates on maximum application to demand in surgical, trauma, and emergency care environments. Thus, it invariably demands high usage in hospitals and clinics.

Moreover, hospitals also apply Factor IX and Factor XIII to treat bleeding disorders and prophylactically before surgery in hemophilic patients. In addition, hemophilia treatment centers (HTC) clinics in hospitals are essential in ensuring proper diagnosis and timely transfusion of appropriate coagulant therapies for hospitals.

Provides hospitals in North America, Europe, and emerging industries in Asia-Pacific with wide access to recombinant and plasma-derived coagulation factors developed by leading pharmaceutical companies such as CSL Behring, Takeda Pharmaceuticals, Pfizer, and Novo Nordisk.

Another 20% goes to research laboratories and is caused by studies undertaken in hematology, gene therapy, and the development of next-generation products for coagulation factors. Research in innovative therapeutic approaches toward bleeding disorders largely focuses on avenues introduced by personalized medicine and new gene-editing technologies.

A significant investment in gene therapy trials using CRISPR-based and AAV (adeno-associated virus) vector therapies to offer long-lasting cures for hemophilia is being made by academic institutions, biotechnology companies, and research organizations. The process used is gene therapy, which provides solutions for lifelong infusions of coagulation factor in hemophilia patients, such as Sangamo Therapeutics and Spark Therapeutics.

Competitive Outlook

The coagulation factor concentrate market is showing consistent growth due to the increasing incidence of hemophilia along with bleeding disorders and the enhancement of plasma-derived and recombinant therapies. The advancement of growth technology and increased accessibility in emerging industries have enhanced therapeutic options and availability, leading to competition among local and multinational majors.

CSL Behring is the leader in its extensive portfolio of plasma-derived and recombinant factor concentrates with backing from in-depth distribution channels and global manufacturing capacity. Baxter International, through product focus and partnerships, has a dominant share, particularly for recombinant therapy. Grifols has a robust presence through vertically integrated business models, taking advantage of plasma sourcing and ownership of production in several geographies.

Novo Nordisk and Octapharma are emerging as major players, fueled by technological developments in recombinant factor technology and patient-centric treatment models. Research-driven strategic investments and improved half-life products have enabled these players to enhance patient compliance and treatment outcomes. The competitive landscape remains dynamic, with local players and public sector manufacturers also making major share gains through national supply contracts and cost-effective solutions.

Market Share Analysis by Company

Company Name	Estimated Market Share (%)
CSL Behring	22-25%
Grifols	16-18%
Baxter International Inc.	13-15%
Novo Nordisk A/S	10-12%
Octapharma	9-11%
Other Companies Combined	20-30%

Key Company Offerings and Activities

Company Name	Key Offerings/Activities
CSL Behring	Offers plasma-derived and recombinant therapies; advanced manufacturing, global access, and wide clinical pipeline.
Grifols	Integrated plasma collection and factor production; expanded access in emerging industries and sustainable supply chain strategies.
Baxter International Inc.	Provides recombinant factor VIII and IX products; focuses on hemophilia innovation and collaboration with care networks.
Novo Nordisk A/S	It specializes in long-acting recombinant therapies and uses a patient-centric approach with home treatment support systems.
Octapharma	Offers plasma-derived factor VIII products; invests in high-purity factor innovations and personalized treatment support.

Key Company Insights

CSL Behring (22-25%)

Leading through strong R&D in long-acting therapies, CSL Behring continues expanding in emerging industries while ensuring robust plasma supply through strategic center acquisitions.

Grifols (16-18%)

Grifols leverages vertical integration across its plasma facilities to meet global demand, with an increased focus on recombinant R&D and access strategies for lower-income regions.

Baxter International Inc. (13-15%)

 Baxter emphasizes innovation in hemophilia therapy through sustained investments in Factor IX products and builds strong partnerships to enhance therapeutic coverage globally.

Novo Nordisk A/S (10-12%)

 Novo Nordisk focuses on long-duration recombinant therapies with fewer infusions, aligning with treatment compliance trends and expanding support programs for home therapy.

Octapharma (9-11%)

Octapharma’s specialization in plasma-based treatments and investments in high-purity and low-immunogenicity factor VIII products strengthen its niche presence globally.

Other Key Players (30-40% Combined)

• Shire
• Kedrion S.P.A.
• LFB
• Biotest
• Green Cross Corporation
• Shanghai RAAS Blood Products
• Sanquin
• Bio Product Laboratory
• Medscape

Key Players

• CSL Behring
• Grifols
• Baxter International Inc.
• Novo Nordisk A/S
• Octapharma
• Shire
• Kedrion S.P.A.
• LFB
• Biotest
• Green Cross Corporation
• Shanghai RAAS Blood Products
• Sanquin
• Bio Product Laboratory
• Medscape

Segmentation

By Type :

The segmentation is into Coagulation Factor IX, Coagulation Factor XIII, and Other Types, addressing various blood clotting disorders.

By End User :

The segmentation is into Hospitals & Clinics, Research Laboratories, and Academic Institutions, catering to both medical treatment and research needs.

By Region :

The segmentation is into North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa (MEA), reflecting global demand for coagulation factors.